New formulations of existing antidepressants: advantages in the management of depression.

abstract：:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...

journal_title：CNS drugs

authors： Pae CU,Patkar AA

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE:The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose i...

journal_title：CNS drugs

authors： Lin FJ,Lin HW,Ho YF

更新日期：2018-04-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：CNS drugs

authors： Chidambaran V,Costandi A,D'Mello A

更新日期：2018-09-01 00:00:00

abstract：:Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...

journal_title：CNS drugs

authors： Knupp KG,Wirrell EC

更新日期：2018-04-01 00:00:00

abstract：:In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxi...

journal_title：CNS drugs

authors： Berman K,Brodaty H

更新日期：2004-01-01 00:00:00

abstract：:The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

journal_title：CNS drugs

authors： Jones JD

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...

journal_title：CNS drugs

authors： Cook AM,Zafar MS,Mathias S,Stewart AM,Albuja AC,Bensalem-Owen M,Kapoor S,Baumann RJ

更新日期：2016-01-01 00:00:00

abstract：:The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...

journal_title：CNS drugs

authors： Kelley BJ,Glasser S

更新日期：2014-05-01 00:00:00

abstract：:Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

journal_title：CNS drugs

authors： Hesse LM,von Moltke LL,Greenblatt DJ

更新日期：2003-01-01 00:00:00

abstract：:How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

journal_title：CNS drugs

authors： Kingsberg SA,Clayton AH,Pfaus JG

更新日期：2015-11-01 00:00:00

abstract：:Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

journal_title：CNS drugs

authors： Maghzi AH,Minagar A,Waubant E

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...

journal_title：CNS drugs

authors： Askari N,Moin M,Sanati M,Tajdini M,Hosseini SM,Modabbernia A,Najand B,Salimi S,Tabrizi M,Ashrafi M,Hajiaghaee R,Akhondzadeh S

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

journal_title：CNS drugs

authors： Sutter R,Marsch S,Rüegg S

更新日期：2013-04-01 00:00:00

abstract：:Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imagi...

journal_title：CNS drugs

authors： Anlar B

更新日期：1997-02-01 00:00:00

abstract：BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...

journal_title：CNS drugs

authors： Söderberg KC,Laflamme L,Möller J

更新日期：2013-02-01 00:00:00

abstract：:Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

journal_title：CNS drugs

authors： Deeks ED,Keating GM

更新日期：2010-01-01 00:00:00

abstract：INTRODUCTION:Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insuli...

journal_title：CNS drugs

authors： Rosenbloom MH,Barclay TR,Pyle M,Owens BL,Cagan AB,Anderson CP,Frey WH 2nd,Hanson LR

更新日期：2014-12-01 00:00:00

abstract：:Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

journal_title：CNS drugs

authors： Bakish D,Habib R,Hooper CL

更新日期：1998-04-01 00:00:00

abstract：:Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

journal_title：CNS drugs

authors： Alda M

更新日期：2019-08-01 00:00:00

abstract：:Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

journal_title：CNS drugs

authors： Tsou AY,Friedman LS,Wilson RB,Lynch DR

更新日期：2009-01-01 00:00:00

abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

journal_title：CNS drugs

authors： Connor DF,Steingard RJ

更新日期：2004-01-01 00:00:00

abstract：:There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...

journal_title：CNS drugs

authors： Varley CK

更新日期：2006-01-01 00:00:00

abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

journal_title：CNS drugs

authors： Papadopoulos D,Mitsikostas DD

更新日期：2019-01-01 00:00:00

abstract：:Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...

journal_title：CNS drugs

authors： Chronis-Tuscano A,Stein MA

更新日期：2012-09-01 00:00:00

abstract：:In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...

journal_title：CNS drugs

authors： Deckers CL,Knoester PD,de Haan GJ,Keyser A,Renier WO,Hekster YA

更新日期：2003-01-01 00:00:00

abstract：:Much work has been carried out in recent years showing that elevated glutamate levels in the extracellular environment of the central nervous system play a pivotal role in neurodegeneration in acute CNS injuries. With the elucidation of the mechanism governing glutamate excitotoxicity, researchers are devising therape...

journal_title：CNS drugs

authors： Jia M,Njapo SA,Rastogi V,Hedna VS

更新日期：2015-02-01 00:00:00

abstract：:This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

journal_title：CNS drugs

authors： Jennings MT,Iyengar S

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Valproate is a first-line antiepileptic agent and is also used in the treatment of bipolar disorder and migraine. It is a known human teratogen. The objective of the study was to evaluate the teratogenic risk of valproate. METHODS:All callers who contacted the Israeli Teratology Information Service (TIS) be...

journal_title：CNS drugs

authors： Diav-Citrin O,Shechtman S,Bar-Oz B,Cantrell D,Arnon J,Ornoy A

更新日期：2008-01-01 00:00:00

abstract：:Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...

journal_title：CNS drugs

authors： Abudy A,Juven-Wetzler A,Zohar J

更新日期：2011-07-01 00:00:00

abstract：:Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...

journal_title：CNS drugs

authors： Syed YY,Keating GM

更新日期：2013-10-01 00:00:00